Do analysts recommend APVO or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aptevo Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, APVO or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Aptevo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aptevo Therapeutics N/A N/A -$25.97M -$197.60 N/A Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A

Is APVO or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Aptevo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aptevo Therapeutics N/A -198.50% -117.06% Universe Pharmaceuticals N/A N/A N/A

Do analysts rate BCAB or UPC?

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 5,606.13%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioAtla 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BCAB or UPC?

Universe Pharmaceuticals has higher revenue and earnings than BioAtla. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAtla $2M 2.91 -$59.61M -$41.72 N/A Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A

Is BCAB or UPC more profitable?

Company Net Margins Return on Equity Return on Assets BioAtla N/A N/A -325.64% Universe Pharmaceuticals N/A N/A N/A

Do analysts recommend RNAZ or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, RNAZ or UPC?

Universe Pharmaceuticals has higher revenue and earnings than TransCode Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A

Is RNAZ or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Universe Pharmaceuticals N/A N/A N/A

Do analysts rate UPC or SNGX?

Soligenix has a consensus target price of $6.00, suggesting a potential upside of 1,155.23%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation and earnings, UPC or SNGX?

Universe Pharmaceuticals has higher revenue and earnings than Soligenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A Soligenix $120K 59.03 -$11.08M -$1.68 N/A

Is UPC or SNGX more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Soligenix N/A -244.73% -131.22%

Do analysts rate INM or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, INM or UPC?

Universe Pharmaceuticals has higher revenue and earnings than InMed Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMed Pharmaceuticals $4.94M 1.08 -$8.16M -$2.89 N/A Universe Pharmaceuticals $17.86M 0.10 -$3.67M N/A N/A

Universe Pharmaceuticals (UPC) Competitors

$3.34 -0.10 (-2.76%)

As of 03:11 PM Eastern

Compare

UPC vs. APVO, BCAB, RNAZ, SNGX, and INM

Should you buy Universe Pharmaceuticals stock or one of its competitors? MarketBeat compares Universe Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Universe Pharmaceuticals include Aptevo Therapeutics (APVO), BioAtla (BCAB), TransCode Therapeutics (RNAZ), Soligenix (SNGX), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical products" industry.

How does Universe Pharmaceuticals compare to Aptevo Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Universe Pharmaceuticals has higher revenue and earnings than Aptevo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptevo Therapeutics	N/A	N/A	-$25.97M	-$197.60	N/A
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptevo Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aptevo Therapeutics had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Aptevo Therapeutics and 0 mentions for Universe Pharmaceuticals. Aptevo Therapeutics' average media sentiment score of 0.62 beat Universe Pharmaceuticals' score of 0.44 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aptevo Therapeutics	Positive
Universe Pharmaceuticals	Neutral

Universe Pharmaceuticals' return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptevo Therapeutics	N/A	-198.50%	-117.06%
Universe Pharmaceuticals	N/A	N/A	N/A

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are owned by institutional investors. 0.1% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aptevo Therapeutics has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the broader market.

Summary

Aptevo Therapeutics beats Universe Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to BioAtla?

BioAtla (NASDAQ:BCAB) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Universe Pharmaceuticals has higher revenue and earnings than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	2.91	-$59.61M	-$41.72	N/A
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A

In the previous week, BioAtla had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for BioAtla and 0 mentions for Universe Pharmaceuticals. BioAtla's average media sentiment score of 0.93 beat Universe Pharmaceuticals' score of 0.44 indicating that BioAtla is being referred to more favorably in the media.

Company	Overall Sentiment
BioAtla	Positive
Universe Pharmaceuticals	Neutral

77.2% of BioAtla shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 11.8% of BioAtla shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioAtla has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-325.64%
Universe Pharmaceuticals	N/A	N/A	N/A

BioAtla currently has a consensus target price of $200.00, suggesting a potential upside of 5,606.13%. Given BioAtla's stronger consensus rating and higher possible upside, analysts plainly believe BioAtla is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioAtla beats Universe Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, TransCode Therapeutics had 2 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 2 mentions for TransCode Therapeutics and 0 mentions for Universe Pharmaceuticals. TransCode Therapeutics' average media sentiment score of 0.46 beat Universe Pharmaceuticals' score of 0.44 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
Universe Pharmaceuticals	Neutral

0.2% of Universe Pharmaceuticals shares are held by institutional investors. 0.0% of TransCode Therapeutics shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Universe Pharmaceuticals	N/A	N/A	N/A

TransCode Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, meaning that its share price is 60% more volatile than the broader market.

Universe Pharmaceuticals has higher revenue and earnings than TransCode Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A

Summary

Universe Pharmaceuticals beats TransCode Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Soligenix?

Universe Pharmaceuticals (NASDAQ:UPC) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Universe Pharmaceuticals has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.84, suggesting that its share price is 84% more volatile than the broader market.

Universe Pharmaceuticals has higher revenue and earnings than Soligenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A
Soligenix	$120K	59.03	-$11.08M	-$1.68	N/A

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by insiders. Comparatively, 3.1% of Soligenix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Soligenix	N/A	-244.73%	-131.22%

Soligenix has a consensus target price of $6.00, suggesting a potential upside of 1,155.23%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Soligenix had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 1 mentions for Soligenix and 0 mentions for Universe Pharmaceuticals. Soligenix's average media sentiment score of 1.38 beat Universe Pharmaceuticals' score of 0.44 indicating that Soligenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Soligenix	Positive

Summary

Soligenix beats Universe Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to InMed Pharmaceuticals?

InMed Pharmaceuticals (NASDAQ:INM) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

InMed Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, InMed Pharmaceuticals' average media sentiment score of 1.66 beat Universe Pharmaceuticals' score of 0.44 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
InMed Pharmaceuticals	Very Positive
Universe Pharmaceuticals	Neutral

Universe Pharmaceuticals has higher revenue and earnings than InMed Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	1.08	-$8.16M	-$2.89	N/A
Universe Pharmaceuticals	$17.86M	0.10	-$3.67M	N/A	N/A

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Universe Pharmaceuticals has a net margin of 0.00% compared to InMed Pharmaceuticals' net margin of -132.87%. Universe Pharmaceuticals' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	-132.87%	-80.85%	-68.11%
Universe Pharmaceuticals	N/A	N/A	N/A

Summary

Universe Pharmaceuticals beats InMed Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPC vs. The Competition

Export

Metric	Universe Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.87M	$2.96B	$6.43B	$12.49B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	N/A	18.10	23.86	24.42
Price / Sales	0.10	298.31	521.12	117.04
Price / Cash	N/A	55.72	41.27	57.13
Price / Book	0.03	3.94	10.04	6.74
Net Income	-$3.67M	$75.85M	$3.56B	$337.03M
7 Day Performance	14.55%	-1.40%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-20.73%	22.88%	28.80%	34.36%

Universe Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0.4404 of 5 stars	$3.35 -2.8%	N/A	-25.9%	$1.87M	$17.86M	N/A	220	Gap Down
APVO Aptevo Therapeutics	1.269 of 5 stars	$4.95 flat	N/A	-94.4%	$6.17M	N/A	N/A	50
BCAB BioAtla	1.5342 of 5 stars	$3.69 flat	$200.00 +5,320.1%	-87.0%	$6.11M	$2M	N/A	60
RNAZ TransCode Therapeutics	0.3585 of 5 stars	$6.24 flat	N/A	-28.3%	$5.93M	N/A	N/A	9	News Coverage Gap Down
SNGX Soligenix	3.2048 of 5 stars	$0.39 flat	$6.00 +1,438.1%	-75.2%	$5.78M	$120K	N/A	20	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Universe Pharmaceuticals (UPC) Competitors

UPC vs. APVO, BCAB, RNAZ, SNGX, and INM

How does Universe Pharmaceuticals compare to Aptevo Therapeutics?

Summary

How does Universe Pharmaceuticals compare to BioAtla?

Summary

How does Universe Pharmaceuticals compare to TransCode Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Soligenix?

Summary

How does Universe Pharmaceuticals compare to InMed Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Universe Pharmaceuticals (UPC) Competitors

UPC vs. APVO, BCAB, RNAZ, SNGX, and INM

How does Universe Pharmaceuticals compare to Aptevo Therapeutics?

Which has stronger earnings & valuation, APVO or UPC?

Do analysts recommend APVO or UPC?

Does the media refer more to APVO or UPC?

Is APVO or UPC more profitable?

Do institutionals and insiders hold more shares of APVO or UPC?

Which has more volatility & risk, APVO or UPC?

Summary

How does Universe Pharmaceuticals compare to BioAtla?

Which has better earnings & valuation, BCAB or UPC?

Does the media refer more to BCAB or UPC?

Do institutionals and insiders have more ownership in BCAB or UPC?

Which has more risk and volatility, BCAB or UPC?

Is BCAB or UPC more profitable?

Do analysts rate BCAB or UPC?

Summary

How does Universe Pharmaceuticals compare to TransCode Therapeutics?

Do analysts recommend RNAZ or UPC?

Does the media favor RNAZ or UPC?

Do insiders and institutionals have more ownership in RNAZ or UPC?

Is RNAZ or UPC more profitable?

Which has more volatility & risk, RNAZ or UPC?

Which has better valuation and earnings, RNAZ or UPC?

Summary

How does Universe Pharmaceuticals compare to Soligenix?

Which has more risk & volatility, UPC or SNGX?

Which has preferable valuation and earnings, UPC or SNGX?

Do insiders & institutionals hold more shares of UPC or SNGX?

Is UPC or SNGX more profitable?

Do analysts rate UPC or SNGX?

Does the media refer more to UPC or SNGX?

Summary

How does Universe Pharmaceuticals compare to InMed Pharmaceuticals?

Which has more volatility and risk, INM or UPC?

Do analysts rate INM or UPC?

Does the media favor INM or UPC?

Which has preferable earnings and valuation, INM or UPC?

Do institutionals & insiders hold more shares of INM or UPC?

Is INM or UPC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools